Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) | Apply Online

Opportunity Summary:

The Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) opportunity (Funding Opportunity Number PAR 14 192) is a National Institutes of Health program administered through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Its central purpose is to move promising, patient-focused intervention ideas into early clinical testing by supporting exploratory interventional clinical trials that can show clinically meaningful improvement in symptoms, physical function, or the overall course of rheumatic, musculoskeletal, or skin diseases. The emphasis is on generating practical human data that can either justify and shape a later, larger and more definitive trial or directly inform clinical decision making at the individual patient level.

The scope of supported studies is intentionally broad as long as the work aligns with the NIAMS mission and goals. Applicants can propose trials evaluating drugs, biologics, devices, and surgical approaches, as well as dietary, behavioral, rehabilitation, or other therapeutic strategies relevant to arthritis and related musculoskeletal and skin conditions. The FOA is built around the idea that many high-potential interventions stall because there is not enough early clinical evidence to de-risk a larger investment. This program is meant to close that gap by funding short-term, creative, and targeted trials designed to produce the kind of experimental clinical data that helps determine whether an intervention is worth pursuing in a more robust clinical trial pipeline.

A defining feature of this opportunity is its encouragement of innovation in both the research question and the trial approach. Proposed trials are expected to investigate new ideas, and the FOA explicitly allows for creative trial designs suitable for early-stage clinical testing. In practice, that means the program is geared toward studies that are nimble and informative rather than large and confirmatory. The ideal application is one that uses an interventional trial to answer a focused question that matters clinically, such as whether a new therapeutic approach shows a signal of benefit on a meaningful patient-centered outcome, whether it is feasible to deliver in real-world settings, whether it affects a mechanistic or intermediate endpoint that is strongly tied to patient outcomes, or whether it clarifies which subgroup of patients is most likely to benefit.

From a funding mechanics perspective, this is a discretionary grant program using the NIH R21 activity mechanism, which is commonly used for exploratory and developmental projects. The listed award ceiling is $400,000. There is no cost sharing or matching requirement, which means applicants are not required to provide non-federal matching funds as a condition of the award. The program sits within the NIH health funding activity category and is associated with CFDA number 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).

Eligibility is expansive and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status (with some distinctions noted in the FOA), for-profit organizations other than small businesses, and small businesses. A wide range of government entities may apply as well, including state governments, county governments, city or township governments, special district governments, public housing authorities or Indian housing authorities, and tribal governments or tribal organizations (with both federally recognized and other tribal entities referenced). The FOA also explicitly recognizes additional eligible applicant categories such as Historically Black Colleges and Universities, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions, along with faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, the announcement makes clear that non-U.S. (foreign) institutions are not eligible to apply directly, and non-U.S. components of U.S. organizations are not eligible; however, foreign components as defined by NIH policy are allowed, which typically means limited, well-justified portions of the work can be carried out abroad under a U.S. applicant organization when appropriate.

Timing information in the source indicates the opportunity was posted and created on April 24, 2014, with an original and current closing date of March 1, 2017, and an archive date of April 1, 2017. Those dates indicate it is no longer active, but the summary still describes the intent and structure of the program while it was open. The full announcement was available through the NIH Grants Guide at the link provided in the source (PAR 14 192), and NIH Office of Extramural Research webmaster contacts were listed for access or linking issues.

Overall, this FOA is best understood as NIAMS support for early, interventional clinical trials that are designed to be short-term, hypothesis-driven, and clinically relevant, with the explicit aim of producing actionable evidence. It is not positioned as a large definitive efficacy program; instead, it is meant to help investigators test new clinical ideas in patients in a disciplined way, refine how an intervention should be deployed, and generate the kind of results that either justify a larger follow-on trial or meaningfully guide patient-level clinical choices.

Browse more business programs for Skin Diseases Research

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Farm Business Management and Benchmarking Competitive Grants Program

Previous opportunity: Rural Health and Safety Education

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 14 192

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 14 192) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 192", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.